Literature DB >> 3102483

Thrombin interaction with platelets. Influence of a platelet protease nexin.

R S Gronke, B L Bergman, J B Baker.   

Abstract

A fraction of the 125I-thrombin that binds to human platelets is taken into a sodium dodecyl sulfate-resistant 77 kDa complex with a platelet factor (Bennett, W. F., and Glenn, K. C. (1980) Cell 22, 621-627). Here we show that this platelet factor is in several respects similar to protease nexin I (PNI), a fibroblast thrombin inhibitor. The complexes are of the appropriate size, bind to Sepharose that has been derivatized with anti-PNI antibody, do not form when the thrombin active site has been blocked with diisopropylphosphofluoridate, and do not appear on platelets when heparin is present. However, the platelet factor does not bind urokinase, indicating that this "platelet PN" may be distinct from PNI. Following brief incubation with 125I-thrombin, platelet PN X 125I X thrombin complexes are found both associated with the platelets and free in the binding medium. 125I-Thrombin has a higher affinity for platelet PN than for platelet receptors. In 30-s binding incubations carried out with thrombin at concentrations below 0.3 nM, formation of the 77-kDa complex accounts for most of the platelet specific binding of 125I-thrombin. Subtracting this large contribution to 125I-thrombin-specific binding reveals that the reversible binding of 125I-thrombin to platelet receptors exhibits sigmoidal thrombin dose-dependence. Thrombin stimulation of platelet [14C]serotonin release exhibits similar thrombin dose dependence. These results indicate that platelets may possess a mechanism for suppressing their interaction with active thrombin at thrombin doses below 0.3 nM. It is possible that platelet PN carries out this function by capturing thrombin before thrombin binds to its signal-transmitting receptors.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3102483

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

Review 1.  Regulation of renal sodium handling through the interaction between serine proteases and serine protease inhibitors.

Authors:  Kenichiro Kitamura; Kimio Tomita
Journal:  Clin Exp Nephrol       Date:  2010-06-11       Impact factor: 2.801

Review 2.  Characterization of a functional thrombin receptor. Issues and opportunities.

Authors:  S R Coughlin; T K Vu; D T Hung; V I Wheaton
Journal:  J Clin Invest       Date:  1992-02       Impact factor: 14.808

Review 3.  Proteolytic activation of the epithelial sodium channel and therapeutic application of a serine protease inhibitor for the treatment of salt-sensitive hypertension.

Authors:  Kenichiro Kitamura; Kimio Tomita
Journal:  Clin Exp Nephrol       Date:  2011-11-01       Impact factor: 2.801

4.  Serpin targets in hemostasis/kinin formation.

Authors:  Alvin H Schmaier
Journal:  Blood       Date:  2019-11-07       Impact factor: 22.113

5.  Interaction of activated protein C with serpins.

Authors:  J M Hermans; S R Stone
Journal:  Biochem J       Date:  1993-10-01       Impact factor: 3.857

6.  Agents that elevate the concentration of cAMP in platelets inhibit the formation of a NaDodSO4-resistant complex between thrombin and a 40-kDa protein.

Authors:  K M Lerea; J A Glomset
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

7.  The serine protease granzyme A does not induce platelet aggregation but inhibits responses triggered by thrombin.

Authors:  H S Suidan; K J Clemetson; M Brown-Luedi; S P Niclou; J M Clemetson; J Tschopp; D Monard
Journal:  Biochem J       Date:  1996-05-01       Impact factor: 3.857

8.  Effect of heparin on the glia-derived-nexin-thrombin interaction.

Authors:  A Wallace; G Rovelli; J Hofsteenge; S R Stone
Journal:  Biochem J       Date:  1989-01-01       Impact factor: 3.857

9.  Thrombin interaction with a recombinant N-terminal extracellular domain of the thrombin receptor in an acellular system.

Authors:  M C Bouton; M Jandrot-Perrus; S Moog; J P Cazenave; M C Guillin; F Lanza
Journal:  Biochem J       Date:  1995-01-15       Impact factor: 3.857

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.